Experts in Endocrinology
At Dechra, we are committed to providing veterinarians with innovative tools and resources to support in endocrine cases
Below are details of some of our latest initiatives which may be of interest to you.
Dechra Endocrinology App
Our Endocrinology App, is designed to help veterinarians better diagnose and treat endocrine disorders in their animal patients.
The app provides veterinarians with a prediction of how likely a dog is to have Cushing’s syndrome based on its clinical signs and supports effective diagnosis. With additional information on the treatment and monitoring of Cushing’s and Addison’s, the app helps veterinarians better understand endocrine disorders and stay up to date with the latest information provided by Dechra. The Dechra Endocrinology App is available for free download on both Apple and Android devices. Veterinarians can access the app's features and resources at any time, making it a convenient and valuable tool to have on hand.
Download now
Dechra Connect Series
Dechra Connect series are designed to help veterinarians better diagnose and treat endocrine disorders in their animal patients. They aim to help refresh endocrine knowledge through informative bitesize learning modules.
The websites also host an extensive library of learning resources providing vets with the confidence to successfully diagnose, treat and monitor Cushing's, as well as FAQs to help assist and refresh knowledge when it is needed the most.
To find out more visit:
Cushing's Monitoring App for owners
The Cushing's Monitoring App is a digital solution specially designed to aid dog owners in monitoring and managing Canine Cushing's syndrome. Recognising the challenges faced by dog owners in monitoring this disease, the Vetoryl Monitoring App aims to simplify, streamline, and enhance the management process.
Key features of the Cushing's Monitoring App:
Daily Monitoring: Owners can effortlessly track their dog's daily symptoms, including appetite, water consumption, and energy levels.
Medication Reminders: Ensure timely administration of Vetoryl with customisable medication reminders.
Enhanced Collaboration: As owners monitor their dogs, you gain deeper insights. Understand each dog's condition more intimately for precise care.
Download now
Dechra Technical team
With 20 years of supporting you in endocrine cases, our Technical team are able to help if you are struggling to reach a conclusion or have a question with regards to an endocrine patients.
Availble soon - NEW double divisible Vetoryl Chewable tablet
We are pleased to announce the launch of Vetoryl Chewable tablets®. Containing trilostane, Vetoryl tablets are double divisible, flavoured and are available in 20 mg, 30 mg and 60 mg strengths.
Backed by 20 years of experience and knowledge in Cushing’s the launch of a double-divisible Vetoryl tablet demonstrates our ongoing commitment to improving the treatment of Cushing’s.
To be the first to know more, register your interest here
Felimazole - now available in an oral solution
Offering flexibility and precision, Felimazole helps you to take control of hyperthyroidism. Felimazole offers a versatile approach with the option of both oral solution and tablet formulations, allowing you to customise treatment to suit your patients' requirements and accommodate owners' preferences.
Introducing Felimazole Oral Solution:
- Felimazole Oral Solution 5 mg/ml contains thiamazole
- Available in 30 ml or 100 ml bottle with a dosing syringe
- Honey flavoured
- 2 years shelf life, 6 months broached shelf life
To find out more click here
Long-acting insulins for dogs and cats
Dechra has partnered with Akston to develop an innovative treatment for diabetes control in dogs and cats based on bioengineered polypeptides (Fc-fusion proteins) manufactured by specialized cell lines.
The Fc fusion proteins consist of the fusion of a modified human insulin to the Fc domain of canine or feline gamma immunoglobulin (IgG).
The fusion protein has an plasma half-life because it recycles through cells, protected from proteolysis, significantly decreasing treatment frequency.
MECHANISM OF ACTION
The fusion protein has a long plasma half-life because it recycles through cells, protected from proteolysis, significantly decreasing treatment frequency.
Become a Clinical Trial Investigator
Learn more about Dechra's clinical trial opportunities and how you can serve as an investigator
